Onchocerciasis

Global donors pledge over US$777 million to defeat neglected tropical diseases and improve the lives of 1.6 billion people at the Reaching the Last Mile Forum at COP28

Retrieved on: 
Sunday, December 3, 2023
Philanthropy, Health, Infectious Diseases, Other Health, Fund Raising, Foundation, General Health, Lymphatic filariasis, Global health, Climate change, WHO, Investment, Map, Public holidays in Turkmenistan, ANESVAD Foundation, Onchocerciasis, Conference, Quality of life, RLM, NTD, Organization, Prevalence, USAID, Multimedia, Melinda French Gates, Helmsley, Neglected tropical diseases, Carter Center, Closed-end fund, Face, Bill, The Fred Hollows Foundation, Foreign Affairs, Laboratory, Infection, Partnership, World Health Organization, Research, Dracunculiasis, Hope, COP28, Carter, Poverty, Demographics of Tanzania, LF, RVNG Intl., Trypanosomiasis, Medical device, Renewable energy, Pharmaceutical industry, Agriculture, Sanitation

The forum took place on the first ever Health Day during the United Nations Climate Change Conference (COP28).

Key Points: 
  • The forum took place on the first ever Health Day during the United Nations Climate Change Conference (COP28).
  • His Highness Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs, UAE, was joined by world leaders including H.E.
  • Dr Austin Demby, Minister of Health and Sanitation, Sierra Leone, in a demonstration of endemic country leadership against NTDs.
  • The collaborative efforts of countries and global donors exemplify an unwavering dedication to improving the lives of the 1.6 billion people affected by these diseases.

New York Blood Center Enterprises Grants Exclusive License to Big Eye Diagnostics for Diagnostic Biomarkers in River Blindness

Retrieved on: 
Wednesday, November 1, 2023
National Institute of Allergy and Infectious Diseases, WHO, Onchocerciasis, MDA, Biomarker, Infection, NIAID, Research, Laboratory, Disease, World Health Organization, Risk, Mass drug administration, Partnership, Lindsley, Poverty, Onchocerca volvulus, NIH, Diagnosis, Bangladesh Technical Education Board, Pharmaceutical industry, Medical device

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) announced today it granted an exclusive commercial license to Big Eye Diagnostics for the rights to develop a diagnostic tool for onchocerciasis or river blindness.

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) announced today it granted an exclusive commercial license to Big Eye Diagnostics for the rights to develop a diagnostic tool for onchocerciasis or river blindness.
  • River Blindness impacts 18 million individuals, with an additional 218 million at risk of contracting the disease.
  • Furthermore, the resulting solution could streamline deployment in the affected geographies, addressing a significant need in the fight against river blindness.
  • "This innovative work from NYBC and NIH provides the necessary foundation to improve diagnosis in a global effort to eliminate river blindness."

A Total of Approximately 400 Million Yen Investment in Eisai, Ehime University, DNDi and Others for New Drug and Vaccine Development for Neglected Tropical Diseases

Retrieved on: 
Thursday, March 30, 2023
Mycetoma, Vaccine, Partnership, Neglected tropical diseases, Government of Japan, United Nations, Amputation, Onchocerciasis, Eumycetoma, Global Health Innovative Technology Fund, UNDP, Global health, Research, Infection, Attention, Ehime University, Paratriathlon, Fungus, Messenger, University Hospital Bonn, Eisai, PPP, US, Tropical disease, Mahidol University, NTD, Tuberculosis, Patient, Investment, Wellcome, Parasitic disease, Parasitism, United Nations Development Programme, Onchocerca, Bill, Bacteria, WHO, Health, Bill & Melinda Gates Foundation, Pain, Virus, Onchocerca volvulus, Drugs for Neglected Diseases Initiative, World Health Organization, Disease, Malaria, Pharmaceutical industry

The GHIT Fund will invest approximately 300 million yen (US$2.2 million1) in a project by Eisai Co., Ltd. (Eisai) and Drugs for Neglected Diseases initiative (DNDi) for regulatory approval and to prepare for patient access to drugs for eumycetoma.

Key Points: 
  • The GHIT Fund will invest approximately 300 million yen (US$2.2 million1) in a project by Eisai Co., Ltd. (Eisai) and Drugs for Neglected Diseases initiative (DNDi) for regulatory approval and to prepare for patient access to drugs for eumycetoma.
  • Mycetoma, an NTD, is a progressive disease that destroys subcutaneous and deep tissues infected by bacterial or fungal invasion through a wound.
  • We hope this treatment will be quickly approved and reach patients as soon as possible, during GHIT's third five-year plan."
  • The GHIT Fund invests and manages an R&D portfolio of development partnerships aimed at neglected diseases, such as malaria, tuberculosis and neglected tropical diseases that afflict the world's vulnerable and underserved populations.

GHIT Fund Announces New Investments: A Total of 790 Million Yen for Product Development of Neglected Tropical Diseases

Retrieved on: 
Friday, November 11, 2022
Wolbachia, Health, Adult, Investment, Wellcome, Vaccine, United Nations, Global Health Innovative Technology Fund, Partnership, Research, Lymphatic filariasis, Bill & Melinda Gates Foundation, United Nations Development Programme, Malaria, US, Government of Japan, PPP, Lymph, Degenerative disease, Onchocerciasis, Neglected tropical diseases, Tuberculosis, Patient, Elephantiasis, Bill, UNDP, CEO, Pharmaceutical industry

TOKYO, Nov. 10, 2022 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of approximately 790 million yen (US$5.3 million*) to invest in product development for lymphatic filariasis and onchocerciasis, two neglected tropical diseases (NTDs).

Key Points: 
  • TOKYO, Nov. 10, 2022 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of approximately 790 million yen (US$5.3 million*) to invest in product development for lymphatic filariasis and onchocerciasis, two neglected tropical diseases (NTDs).
  • Neglected tropical diseases caused by parasitic infection: New drug development for lymphatic filariasis and onchocerciasis
    Lymphatic filariasis (elephantiasis) and onchocerciasis (river blindness) are two neglected tropical diseases that are caused by parasitic worms.
  • The GHIT Fund invests and manages an R&D portfolio of development partnerships aimed at neglected diseases, such as malaria, tuberculosis and neglected tropical diseases that afflict the world's vulnerable and underserved populations.
  • The GHIT Fund mobilizes the Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases, in collaboration with global partners.

Cameroon and the Mectizan Donation Program sign historic agreement to end neglected tropical diseases

Retrieved on: 
Wednesday, July 20, 2022
Onchocerciasis, Filariasis, NGO, World, Tuberculosis, Population, Center, Research, Tablet, Partnership, Government, Lymphatic filariasis, Merck & Co., Malaria, World Health Organization, Quality of life, LF, Ministry, Merck, SDG, Non-governmental organization, National Center for Research Resources, MDP, Program, United Nations Sustainable Development Group, HIV, Ministry of Public Health (Afghanistan), Public health, Pharmaceutical industry

In the agreement, MDP commits to continuing to make available, free of charge, enough Mectizan for Cameroon's river blindness and LF elimination effort until the World Health Organization declares Cameroon to be free of both diseases.

Key Points: 
  • In the agreement, MDP commits to continuing to make available, free of charge, enough Mectizan for Cameroon's river blindness and LF elimination effort until the World Health Organization declares Cameroon to be free of both diseases.
  • The signing of this agreement is an important step to achieving the elimination targets set by the World Health Organization's Neglected Tropical Diseases Road Map 2021-2030.
  • It will also help to meet the United Nations Sustainable Development Goals (SDG), specifically SDG 3.3to "end the epidemics of HIV, tuberculosis, malaria and neglected tropical diseases" by 2030.
  • The Mectizan Donation Program (MDP) oversees the donation of Mectizan by Merck & Co., Inc., Rahway, New Jersey, USA to eligible countries where river blindness and/or lymphatic filariasis are endemic.

Global Access Diagnostics (GADx) Formed to Expand Affordable Access to Advanced Rapid Diagnostic Technologies

Retrieved on: 
Wednesday, June 15, 2022
Biotechnology, Health, Science, Other Science, Pharmaceutical, Solution, COVID-19, Bill, Global health, CEO, Global South, Company, Onchocerciasis, Leadership, Research, Gaps, GAD, Schistosomiasis, Access Health CT, GAH, Fever Dream, Vaccine, Management, Ol-molog

Global Access Health (GAH), a social enterprise dedicated to providing affordable medical products for global health, today formally introduced its first portfolio company, Global Access Diagnostics (GADx).

Key Points: 
  • Global Access Health (GAH), a social enterprise dedicated to providing affordable medical products for global health, today formally introduced its first portfolio company, Global Access Diagnostics (GADx).
  • GADx has been created to address gaps in the global provision of diagnostics with a focus on expanding affordable access to quality tests.
  • The Company combines expertise in rapid diagnostics development from Mologic Ltd with low-cost manufacturing and scale-up capability of sister company, Global Access Diagnostics (GAD).
  • Through this transaction, the group acquired Mologic and GAD to harness industry-leading expertise in developing and manufacture of rapid diagnostic technologies.

The Worldwide Corneal Transplantation Industry is Expected to Reach $640 Million by 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 21, 2022
Health, Optical, Surgery, People, Degenerative disease, Eye, CAGR, Conjunction (grammar), Corneal transplantation, World Health Organization, WHO, DMEK, Growth, Corneal ulcer, Severe cognitive impairment, Keratitis, World, Hospital, Incidence, Keratoconus, Onchocerciasis, Leprosy, Industry, Corneal opacity, Time, COVID-19, Trichiasis, Fuchs' dystrophy, Cornea, RNIB, Epidemiology, Royal National Institute of Blind People, Patient, Pharmaceutical industry, Marketing, Trachoma, Xerophthalmia

The corneal transplantation market is projected to reach $640.79 million by 2028 from $420.71 million in 2021; it is estimated to grow at a CAGR of 6.2% during 2021-2028.

Key Points: 
  • The corneal transplantation market is projected to reach $640.79 million by 2028 from $420.71 million in 2021; it is estimated to grow at a CAGR of 6.2% during 2021-2028.
  • However, the risks associated with Corneal Transplantation and shortage of donor material hampers the market growth.
  • Corneal blindness has complex epidemiology that includes a broad spectrum of infectious and inflammatory eye diseases causing corneal scars that contribute to functional blindness.
  • Trachoma, corneal ulcers, ophthalmia neonatorum, xerophthalmia, viral infections, onchocerciasis, leprosy, traditional eye medications, and eye injuries lead to corneal blindness.

GLIDE: Yemeni Doctor Wins Global Disease Elimination Award to Help Keep the Country Free of Lymphatic Filariasis

Retrieved on: 
Monday, December 13, 2021
Philanthropy, Health, Infectious Diseases, Foundation, Pharmaceutical, Biotechnology, Award, EXPO, Neglected tropical diseases, Lymphatic filariasis, Health, Poverty, World, Onchocerciasis, Polio, Universal health care, World Health Organization, Achievement, The Global Institute for Tomorrow, Bill, Health status of White Americans, Leprosy, Maltese Falcon Society, The Bill, Partnership, Tameem Al-Kubati, LF, Pharmaceutical industry, Medical device, Management, Malaria, GLIDE, the Falcon Awards for Disease Elimination, GLIDE, THE FALCON AWARDS FOR DISEASE ELIMINATION

Dr Abdul Samid Al-Kubati, a doctor who is leading Yemens efforts to keep the country rid of lymphatic filariasis (LF) has won a Falcon Award for Disease Elimination.

Key Points: 
  • Dr Abdul Samid Al-Kubati, a doctor who is leading Yemens efforts to keep the country rid of lymphatic filariasis (LF) has won a Falcon Award for Disease Elimination.
  • The five winners were announced yesterday by the Global Institute for Disease Elimination (GLIDE) during a Universal Health Coverage Day event at EXPO 2020 Dubai.
  • Dr Al-Kubati beat 220 applicants across 44 countries to become the first Yemeni winner of the Falcon Awards.
  • The Awards invited submissions from organisations in disease-endemic countries whose proposals address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.

GLIDE: Vaccination Incentives and Next Generation Sequencing – Two Pakistani Doctors Employ Innovative Techniques to Eradicate Polio

Retrieved on: 
Monday, December 13, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Method, Award, NIH, Government, Vaccination, EXPO, Neglected tropical diseases, Lymphatic filariasis, Child, Poverty, Last mile, COVID-19, Epidemiology, Polio, National Institute, Universal health care, Foundation for the National Institutes of Health, Disease, Poliovirus, Bill, The Global Institute for Tomorrow, Infection, Onchocerciasis, Aga Khan University, Maltese Falcon Society, The Bill, Public health, Division, Partnership, Assistant, Technology, Certification, Pediatric nursing, Medical device, Vaccine, Pharmaceutical industry, Management, Malaria, Woman, GLIDE, the Falcon Awards for Disease Elimination, GLIDE, THE FALCON AWARDS FOR DISEASE ELIMINATION

Pending further successes, there are plans to scale-up Dr Das approach in all 40 high-risk areas in Pakistan.

Key Points: 
  • Pending further successes, there are plans to scale-up Dr Das approach in all 40 high-risk areas in Pakistan.
  • It is possible his methods could also be used to control other infectious diseases in the region, including COVID-19.
  • With GLIDEs support, my project will focus on improving polio vaccination coverage in these high-risk areas which will hopefully contribute to eradicating this disease from the world.
  • Dr Das and Dr Salman beat 220 applicants across 44 countries to become the first Pakistani winners of the Falcon Awards.

GLIDE: End of Malaria and Lymphatic Filariasis in Sight for Philippines, Says Award-winning Filipino Doctor

Retrieved on: 
Monday, December 13, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Research Institute for Tropical Medicine, Award, EXPO, Neglected tropical diseases, Lymphatic filariasis, Tropical medicine, Android, Poverty, Medical specialty, Polio, Universal health care, Patient, Department, The Global Institute for Tomorrow, Prevalence, Bill, Onchocerciasis, Department of Health (Philippines), Maltese Falcon Society, The Bill, Partnership, LF, Pharmaceutical industry, Medicine, Management, Malaria, GLIDE, the Falcon Awards for Disease Elimination, GLIDE, THE FALCON AWARDS FOR DISEASE ELIMINATION

Great achievements have been made in the Philippines to tackle malaria and LF to date.

Key Points: 
  • Great achievements have been made in the Philippines to tackle malaria and LF to date.
  • However, elimination of these diseases remains problematic, and over the last five years, the country has struggled to reduce their prevalence.
  • Dr Espino beat 220 applicants across 44 countries to become the first Filipino winner of the Falcon Awards.
  • Great achievements have been made towards the 2030 goal of the elimination of malaria and lymphatic filariasis.